Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Italy / NCT07402330
Starting soon Early Phase 1

Pharmacokinetic Study of DA-020

NCT07402330 · tracked via the Priya Life Science Italy tracker
Sponsor
Applied Biology, Inc
Phase
Early Phase 1
Started
2026-04-16
Last updated
2026-04-13

Condition(s) studied

Chemotherapy Induced AlopeciaChemotherapy Side Effects

Investigational drug(s) / intervention(s)

DA-020 (0.1%) →DA-020 (0.2%) →DA-020 (0.5%) →

DA-020 (0.1%): DA-020 (0.1%)

DA-020 (0.2%): DA-020 (0.2%)

DA-020 (0.5%): DA-020 (0.5%)

Study summary

Pharmacokinetic Study of DA-020

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
55 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Healthy females, age 18-55 * BMI: 18-30 kg/m² * Fitzpatrick Skin Types I-IV (to standardize absorption risk) * Scalp free from irritation, dermatologic disease, or damage * Able to refrain from using other topical scalp products Exclusion Criteria: * History of cardiovascular disease, hypertension, or arrhythmia * Scalp infections, wounds, or significant hair loss * Recent use of medications that interfere with CYP enzymes or adrenergic systems * Known sensitivity to phenylephrine or ethanol * Positive drug screen or abnormal ECG at screening

Primary outcome measure(s)

  • Concentration of DA-020 in Serum — Hours [0, 1, 2, 4, 8, 12, 24]
    Determine the amount of Oxymetazoline in serum after 1 time scalp application

Trial sites (2)

FacilityCityRegionStatus
Hospital Samel Manaus Brazil
University of Rome ("G. Marconi") Rome Italy

More Applied Biology, Inc. trials in Italy

Clinical Study of DA-020 for the Treatment of Chemotherapy Induced Alopecia Recruiting
Clinical Study of DA-007 for the Treatment of Chemotherapy Induced Alopecia Starting soon
Pharmacokinetic Study of Topical Phenylephrine Recruiting

Other trials for the same condition

Clinical Study of DA-020 for the Treatment of Chemotherapy Induced Alopecia Recruiting
Clinical Study of DA-007 for the Treatment of Chemotherapy Induced Alopecia Starting soon
Pharmacokinetic Study of Topical Phenylephrine Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07402330 on ClinicalTrials.gov ↗ ← All trials in Italy